A melanoma survivor shares facts and tips about preventing all types of skin cancer.

In the second season of The Fundamentals podcast, co-hosts Kelly Malcom and Jordan Goebig talk to several leading experts from the Medical School about their fields and the fundamental questions they are trying to answer — and discover why U-M is such an amazing place for research. Six new episodes of the popular podcast were released on May 6

Today on The Fundamentals, our guest is Dr. Michelle Kahlenberg, an Associate Professor of Internal Medicine and Dermatology, the Giles Bole and Dorothy Mulkey Research Professor of Rheumatology and the Vice Chair for Basic and Translational Research in Internal Medicine. Her clinical work is centered on the care of patients with lupus, including those with refractory skin disease. In addition to running her lab, she's an active member of the Immunology Training Program and has received national recognition for her research.

The Clinical Trials Support Office (CTSO) is pleased to announce that Mio Nakamura, MD, MS, Clinical Assistant Professor, Dermatology, has been appointed as the new Associate Medical Director of the Michigan Clinical Trials Support Unit (M-CTSU) and Michigan Clinical Research Unit (MCRU). Dr. Nakamura’s appointment will begin July 1, 2024, and is a 2-year term.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Telehealth study of patient portal e-visits by Medicare participants shows few had an interaction for which their provider billed them.

The Department of Dermatology announces the residency class of 2028.

A new study examines dermal injections and their impact on skin aging.

New website to help adolescents with disabilities learn about reproductive health.

New study has identified an enzyme contributing to systemic sclerosis.

With thirteen NIH awards totaling more than $6.2M, our department’s NIH funding grew by nearly 35% during Federal Fiscal Year 2023.

Cases of kidney stones in children are increasing, but parents can minimize the chances their kids develop them.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

Dr. Tejasvi at Michigan Medicine and the VA Ann Arbor Health System Receives VA Connected Care Distinguished Leaders Award.